SCHEMBL8117173

SCHEMBL8117173

NC1(NC(=O)[C@@H]2CCCC[C@H]2C(=O)N2CCC(c3ccc(F)cc3)C2)CC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CTSK P43235 5/20 0.50
▸ CTSB P07858 4/20 0.50
▸ CTSS P25774 4/20 0.50
▸ KCNH2 Q12809 1/20 0.50
▸ RAB9A P51151 3/20 0.47
▸ NPC1 O15118 2/20 0.47
▸ MAPT P10636 2/20 0.47
▸ ATM Q13315 1/20 0.46
▸ SIGMAR1 Q99720 2/20 0.45
▸ ADAM10 O14672 3/20 0.42
▸ ERBB2 P04626 3/20 0.42
▸ ALDH1A1 P00352 1/20 0.41
▸ GAA P10253 1/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ MMP2 P08253 2/20 0.40
▸ PARP10 Q53GL7 1/20 0.39
▸ HSD11B1 P28845 1/20 0.39
▸ FAAH O00519 1/20 0.39
▸ EPHX2 P34913 1/20 0.38
▸ HRH3 Q9Y5N1 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8111801 0.79 RBP4 (0.51) CTSKCTSBCTSS
SCHEMBL8111646 0.74 CTSK (0.58) CTSKCTSBCTSSKCNH2
SCHEMBL8111806 0.74 CTSK (0.57) CTSKCTSBCTSSKCNH2
SCHEMBL8109815 0.74 CTSK (0.69) CTSKCTSBCTSSKCNH2
SCHEMBL8105988 0.74 CTSK (0.69) CTSKCTSBCTSSKCNH2
SCHEMBL8114117 0.74 CTSK (0.60) CTSKCTSBCTSSKCNH2
SCHEMBL30693168 0.72 RAB9A (0.61) RAB9ANPC1MAPTATMALDH1A1
SCHEMBL8110145 0.71 HRH3 (0.50) CTSKCTSBCTSSKCNH2HRH3
SCHEMBL2937126 0.71 RAB9A (0.67) RAB9ANPC1MAPTATMALDH1A1
SCHEMBL2937123 0.71 RAB9A (0.67) RAB9ANPC1MAPTATMALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2009001127-A1 CYANOCYCLOPROPYLCARBOXAMIDES AS CATHEPSIN INHIBITORS ASTRAZENECA AB (SE) 2008-12-31 — — WO disclosed
Send feedback